loading page

CARDIAC BIOMARKERS AND MORTALITY IN COVID-19 INFECTION: A REVIEW
  • +8
  • Angelica Cersosimo,
  • Giuliana Cimino,
  • Greta Pascariello,
  • ludovica amore,
  • fabio alghisi,
  • Edoardo Pancaldi,
  • Nicola Bernardi,
  • Riccardo Inciardi,
  • enrico vizzardi,
  • carlo mario lombardi,
  • marco metra
Angelica Cersosimo
University of Brescia

Corresponding Author:angelica.cersosimo@gmail.com

Author Profile
Giuliana Cimino
University of Brescia
Author Profile
Greta Pascariello
University of Brescia
Author Profile
ludovica amore
University of Brescia
Author Profile
fabio alghisi
University of Brescia
Author Profile
Edoardo Pancaldi
University of Brescia
Author Profile
Nicola Bernardi
University of Brescia
Author Profile
Riccardo Inciardi
University of Brescia
Author Profile
enrico vizzardi
University of Brescia
Author Profile
carlo mario lombardi
University of Brescia
Author Profile
marco metra
University of Brescia
Author Profile

Abstract

Lots of meta-analysis emphasize that a great number of hospitalized patients with moderate and severe forms of COVID-19 developed acute myocardial damage, defined as an increase of cardiac biomarkers, such N-terminal pro–B-type natriuretic peptide (NT-pro-BNP), creatine kinase-myocardial band (CK-MB) and of all type of troponins. The highest mortality rate is related with progressively increasing biomarkers levels and with a history of cardiovascular disease. In fact, the biomarkers dosage should be considered as a prognostic marker in all patients with COVID-19 disease at admission, during hospitalization and in the case of clinical deterioration. The purpose of this review is to evaluate cardiovascular prognostic factors in COVID-19 disease throughout the analysis of cardiac biomarkers to early identify the most serious patients and to optimize their outcomes.